English

MADD: Multi-Agent Drug Discovery Orchestra

Artificial Intelligence 2025-11-13 v1

Abstract

Hit identification is a central challenge in early drug discovery, traditionally requiring substantial experimental resources. Recent advances in artificial intelligence, particularly large language models (LLMs), have enabled virtual screening methods that reduce costs and improve efficiency. However, the growing complexity of these tools has limited their accessibility to wet-lab researchers. Multi-agent systems offer a promising solution by combining the interpretability of LLMs with the precision of specialized models and tools. In this work, we present MADD, a multi-agent system that builds and executes customized hit identification pipelines from natural language queries. MADD employs four coordinated agents to handle key subtasks in de novo compound generation and screening. We evaluate MADD across seven drug discovery cases and demonstrate its superior performance compared to existing LLM-based solutions. Using MADD, we pioneer the application of AI-first drug design to five biological targets and release the identified hit molecules. Finally, we introduce a new benchmark of query-molecule pairs and docking scores for over three million compounds to contribute to the agentic future of drug design.

Keywords

Cite

@article{arxiv.2511.08217,
  title  = {MADD: Multi-Agent Drug Discovery Orchestra},
  author = {Gleb V. Solovev and Alina B. Zhidkovskaya and Anastasia Orlova and Nina Gubina and Anastasia Vepreva and Rodion Golovinskii and Ilya Tonkii and Ivan Dubrovsky and Ivan Gurev and Dmitry Gilemkhanov and Denis Chistiakov and Timur A. Aliev and Ivan Poddiakov and Galina Zubkova and Ekaterina V. Skorb and Vladimir Vinogradov and Alexander Boukhanovsky and Nikolay Nikitin and Andrei Dmitrenko and Anna Kalyuzhnaya and Andrey Savchenko},
  journal= {arXiv preprint arXiv:2511.08217},
  year   = {2025}
}

Comments

EMNLP2025 accepted paper, Findings 2025

R2 v1 2026-07-01T07:32:04.187Z